You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥(300347.SZ)與鴻運華寧生物醫藥簽訂戰略合作協議
格隆匯 04-21 17:43

格隆匯4月21日丨泰格醫藥(300347.SZ)公佈,公司近日與鴻運華寧(杭州)生物醫藥有限公司(“鴻運華寧生物醫藥”)簽署了《戰略合作協議》,雙方將本着優勢互補、精誠合作的原則,在創新醫藥產品的臨牀研究和開發過程中進行全方位長期合作,實現互利共贏。

此次簽署戰略合作協議,雙方將就新藥研發在臨牀監查、數據管理和統計、醫學事務、藥物警戒、質量控制、人員培訓、醫學影像、PK樣品檢測、中心實驗室檢測、實驗測試樣品以及實驗藥品物流等方面進行深度合作。此次雙方達成戰略合作,也將充分發揮泰格醫藥在新藥臨牀研究全過程的專業能力和豐富經驗,助力鴻運華寧生物醫藥加速臨牀研究進程。

鴻運華寧生物醫藥與泰格醫藥將在創新藥物臨牀研究領域開展戰略合作,將更好地藉助雙方資源和能力,加快鴻運華寧生物醫藥在研產品的臨牀開發和上市。如果此協議的條款充分履行將對公司未來的經營業績產生積極影響,可幫助公司獲取新的利潤增長點,符合公司全體股東的利益。具體影響將視項目實施情況而定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account